BibTex RIS Cite

A Case of Dapsone Overdose Induced Methemoglobinemia

Year 2014, Volume: 16 Issue: 3, 40 - 41, 01.12.2014

Abstract

Dapsone is a drug with potent anti-inflammatory and anti-parasitic activities, which waspreviously used almost exclusively for the treatment of leprosy. Dapson rarely induce oxidationof haemoglobin which overwhelms the activity of intrinsic red cell methaemoglobin reductaseresulting in significant methaemoglobinaemia. Methylene blue and hemodialysis are consideredas treatment options of metheamoglobinemia together with supportive treatment. Here in wepresent a case of methemoglobinemia due to intentional ingestion of 4 gr dapson

References

  • Özgencil GE, Hasdoğan M, Can ÖS, Sezer G, Erdoğdu P, Ökten methemoglobineminin dört olguda tartışılması. Türk Anest Rean Der Dergisi 2006;34:327-32. bağlı gelişen
  • Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: Case of the blue lady. Can Fam Physician. 2013;59:958-61.
  • Ashurst JV, Wasson MN, Hauger W, Fritz WT. Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia. J Am Osteopath Assoc. 2010;110:16-20.
  • O’Dwyer D, McElvaney NG. A case of dapsone induced methaemoglobineamia. Ir J Med Sci 2008;177:273-5.
  • Zosel A, Rychter K, Leikin JB. Dapsone-induced methemoglobinemia: case report and literature review. Am J Ther. 2007;14:585-7.
  • Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother. 2011;45:1103-15.
  • Ghatak T, Poddar B, Baronia AK. Dapsone induced methemoglobinemia and hemolysis in a G6PD deficient girl, possibly aggravated by aggressive methylene blue therapy. Indian J Dermatol. 2013;58:410.
  • Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA. Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b 5 reductase activity. J Clin Pharmacol. 2012;52:272-8. Mar 21.

YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU

Year 2014, Volume: 16 Issue: 3, 40 - 41, 01.12.2014

Abstract

Dapson potent antiinflamatuar ve antiparazitik etkileri olan Lepra tedavisi için kullanılan birilaçtır. Nadiren eritrosit içerisinde yer alan hemoglobin redüktaz enzimini inhibe ederek,hemoglobinin oksidasyonunu azaltır. Tedavide metilen mavisi ve hemodiyaliz ve destektedavileri uygulanır. Bu calismamizda, kasıtlı olarak 4 gr Dapson alımına bağlı olusan birmethemoglobinemi tablosunu sunmayı amaçladık

References

  • Özgencil GE, Hasdoğan M, Can ÖS, Sezer G, Erdoğdu P, Ökten methemoglobineminin dört olguda tartışılması. Türk Anest Rean Der Dergisi 2006;34:327-32. bağlı gelişen
  • Burke P, Jahangir K, Kolber MR. Dapsone-induced methemoglobinemia: Case of the blue lady. Can Fam Physician. 2013;59:958-61.
  • Ashurst JV, Wasson MN, Hauger W, Fritz WT. Pathophysiologic mechanisms, diagnosis, and management of dapsone-induced methemoglobinemia. J Am Osteopath Assoc. 2010;110:16-20.
  • O’Dwyer D, McElvaney NG. A case of dapsone induced methaemoglobineamia. Ir J Med Sci 2008;177:273-5.
  • Zosel A, Rychter K, Leikin JB. Dapsone-induced methemoglobinemia: case report and literature review. Am J Ther. 2007;14:585-7.
  • Barclay JA, Ziemba SE, Ibrahim RB. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother. 2011;45:1103-15.
  • Ghatak T, Poddar B, Baronia AK. Dapsone induced methemoglobinemia and hemolysis in a G6PD deficient girl, possibly aggravated by aggressive methylene blue therapy. Indian J Dermatol. 2013;58:410.
  • Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA. Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b 5 reductase activity. J Clin Pharmacol. 2012;52:272-8. Mar 21.
There are 8 citations in total.

Details

Primary Language Turkish
Journal Section Case Report
Authors

İsa Başpınar This is me

Mehmet Akif Karamercan This is me

Figen Coşkun This is me

Yavuz Katırcı This is me

Publication Date December 1, 2014
Published in Issue Year 2014 Volume: 16 Issue: 3

Cite

APA Başpınar, İ., Karamercan, M. A., Coşkun, F., Katırcı, Y. (2014). YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU. Duzce Medical Journal, 16(3), 40-41.
AMA Başpınar İ, Karamercan MA, Coşkun F, Katırcı Y. YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU. Duzce Med J. December 2014;16(3):40-41.
Chicago Başpınar, İsa, Mehmet Akif Karamercan, Figen Coşkun, and Yavuz Katırcı. “YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU”. Duzce Medical Journal 16, no. 3 (December 2014): 40-41.
EndNote Başpınar İ, Karamercan MA, Coşkun F, Katırcı Y (December 1, 2014) YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU. Duzce Medical Journal 16 3 40–41.
IEEE İ. Başpınar, M. A. Karamercan, F. Coşkun, and Y. Katırcı, “YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU”, Duzce Med J, vol. 16, no. 3, pp. 40–41, 2014.
ISNAD Başpınar, İsa et al. “YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU”. Duzce Medical Journal 16/3 (December 2014), 40-41.
JAMA Başpınar İ, Karamercan MA, Coşkun F, Katırcı Y. YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU. Duzce Med J. 2014;16:40–41.
MLA Başpınar, İsa et al. “YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU”. Duzce Medical Journal, vol. 16, no. 3, 2014, pp. 40-41.
Vancouver Başpınar İ, Karamercan MA, Coşkun F, Katırcı Y. YÜKSEK DOZ DAPSON ALIMINA BAĞLI METHEMOGLOBİNEMİ OLGUSU. Duzce Med J. 2014;16(3):40-1.